131 related articles for article (PubMed ID: 20524317)
1. Acute rejection in a highly sensitized lung transplant recipient with pre-formed donor-directed anti-HLA class II antibodies: role of bortezomib therapy.
Stuckey LJ; Kamoun M; Wadhwa A; Samaniego M; Bartos C; Berry J; Mahidhara R; Chang AC; Chan KM
Clin Transpl; 2009; ():471-4. PubMed ID: 20524317
[No Abstract] [Full Text] [Related]
2. Bortezomib rescue in refractory acute humoral rejection--report of a case.
Shapiro R; Basu A; Zeevi A; Lunz J; Mapara M; Randhawa P; Morgan C; Tan HP; Sharma V
Clin Transpl; 2009; ():431-2. PubMed ID: 20524310
[No Abstract] [Full Text] [Related]
3. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.
Stuckey LJ; Kamoun M; Chan KM
Ann Pharmacother; 2012 Jan; 46(1):e2. PubMed ID: 22202499
[TBL] [Abstract][Full Text] [Related]
4. Use of bortezomib for prevention and treatment of rejection in sensitized patients.
Hartono C; Lubetzky M; Aull MJ; Saal S; Figueiro J; Kapur S; Dadhania D
Clin Transpl; 2009; ():499-503. PubMed ID: 20524323
[TBL] [Abstract][Full Text] [Related]
5. Abrogation of anti-HLA antibodies via proteasome inhibition.
Trivedi HL; Terasaki PI; Feroz A; Everly MJ; Vanikar AV; Shankar V; Trivedi VB; Kaneku H; Idica AK; Modi PR; Khemchandani SI; Dave SD
Transplantation; 2009 May; 87(10):1555-61. PubMed ID: 19461494
[TBL] [Abstract][Full Text] [Related]
6. Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates.
Wahrmann M; Haidinger M; Körmöczi GF; Weichhart T; Säemann MD; Geyeregger R; Kikić Z; Prikoszovich T; Drach J; Böhmig GA
Transplantation; 2010 Jun; 89(11):1385-90. PubMed ID: 20335829
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib alone fails to decrease donor specific anti-HLA antibodies: 4 case reports.
Sberro-Soussan R; Zuber J; Suberbielle-Boissel C; Legendre C
Clin Transpl; 2009; ():433-8. PubMed ID: 20524311
[TBL] [Abstract][Full Text] [Related]
8. Desensitization protocol using bortezomib for highly sensitized patients awaiting heart or lung transplants.
Weston M; Rolfe M; Haddad T; Lopez-Cepero M
Clin Transpl; 2009; ():393-9. PubMed ID: 20524304
[TBL] [Abstract][Full Text] [Related]
9. Modulation of antibody response in a sensitized patient with ongoing antibody-mediated injury.
Aull MJ; Saal S; Dadhania D; Hartono C; Kapur S
Clin Transpl; 2009; ():495-8. PubMed ID: 20524322
[No Abstract] [Full Text] [Related]
10. Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report.
Hamawi K; Heilman RL; Mazur MJ; Chakkera HA; Mulligan DC; Moss AA; Mekeel KL; Reddy KS
Clin Transpl; 2009; ():407-14. PubMed ID: 20524306
[No Abstract] [Full Text] [Related]
11. The fate of anti-HLA antibody among renal transplantation recipients treated with bortezomib.
Lonze BE; Dagher NN; Simpkins CE; Singer AL; Segev DL; Zachary AA; Montgomery RA
Clin Transpl; 2009; ():377-84. PubMed ID: 20524301
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib use in chronic antibody-mediated allograft dysfunction: a report of three cases.
Cooper JE; Wiseman AC; Chan L
Clin Transpl; 2009; ():455-9. PubMed ID: 20524314
[No Abstract] [Full Text] [Related]
13. Bortezomib for acute humoral rejection in two repeat transplant recipients.
Hardinger KL; Alford K; Murillo D
Clin Transpl; 2009; ():479-83. PubMed ID: 20524319
[TBL] [Abstract][Full Text] [Related]
14. Antihumoral rejection therapy by proteasome inhibitor bortezomib: a case series.
Lachmann N; Schütz M; Budde K; Schönemann C; Waiser J
Clin Transpl; 2009; ():351-8. PubMed ID: 20527073
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib for the treatment of de novo HLA antibody-related antibody mediated rejection.
Al Meshari K
Clin Transpl; 2009; ():385-6. PubMed ID: 20524302
[No Abstract] [Full Text] [Related]
16. A summary of bortezomib use in transplantation across 29 centers.
Everly MJ
Clin Transpl; 2009; ():323-37. PubMed ID: 20524294
[TBL] [Abstract][Full Text] [Related]
17. Acute humoral rejection in a lung recipient: reversion with bortezomib.
Neumann J; Tarrasconi H; Bortolotto A; Machuca T; Canabarro R; Sporleder H; Fernandes S; Schio S; Costa C; Camargo S; Sanchez L; Camargo J; Perin F; Felicetti J; Michelon T
Transplantation; 2010 Jan; 89(1):125-6. PubMed ID: 20061929
[No Abstract] [Full Text] [Related]
18. Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC.
Pavlakis M
Clin Transpl; 2009; ():343-5. PubMed ID: 20524296
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib in the treatment of antibody-mediated rejection--a report of 3 cases.
Mai HL; Cesbron A; Brouard S; Blanchol G; Cantarovich D; Dantal J; Hourmant M; Lino M; Meurette A; Gosselin M; Abbadie O; Soulillou JP; Giral M
Clin Transpl; 2009; ():361-8. PubMed ID: 20524299
[No Abstract] [Full Text] [Related]
20. Bortezomib in lung transplantation: a promising start.
Neumann J; Schio S; Tarrasconi H; Bortolotto A; Costa C; Machuca T; Camargo S; Sanchez L; Michelon T; Canabarro R; Sporleder H; Fernandes S; Camargo J; Perin F; Felicetti J
Clin Transpl; 2009; ():421-4. PubMed ID: 20524308
[No Abstract] [Full Text] [Related]
[Next] [New Search]
